Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
Introduction: The prognosis of patients undergoing transarterial chemoembolization (TACE) is extremely variable, and a confounding factor is that TACE is often repeated several times. We retrospectively evaluated the accuracy of different prognostic scores and staging systems in estimating overall s...
Gespeichert in:
| Veröffentlicht in: | Liver cancer (Basel ) 2021-04, Vol.10 (2), p.126-136 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 136 |
|---|---|
| container_issue | 2 |
| container_start_page | 126 |
| container_title | Liver cancer (Basel ) |
| container_volume | 10 |
| creator | Campani, Claudia Vitale, Alessandro Dragoni, Gabriele Arena, Umberto Laffi, Giacomo Cillo, Umberto Giannini, Edoardo G. Tovoli, Francesco Rapaccini, Gian Ludovico Di Marco, Maria Caturelli, Eugenio Zoli, Marco Sacco, Rodolfo Cabibbo, Giuseppe Mega, Andrea Guarino, Maria Gasbarrini, Antonio Svegliati-Baroni, Gianluca Foschi, Francesco Giuseppe Biasini, Elisabetta Masotto, Alberto Nardone, Gerardo Raimondo, Giovanni Azzaroli, Francesco Vidili, Gianpaolo Brunetto, Maurizia Rossana Farinati, Fabio Trevisani, Franco Marra, Fabio |
| description | Introduction: The prognosis of patients undergoing transarterial chemoembolization (TACE) is extremely variable, and a confounding factor is that TACE is often repeated several times. We retrospectively evaluated the accuracy of different prognostic scores and staging systems in estimating overall survival (OS) in patients with hepatocellular carcinoma (HCC). Methods: An analysis considering prognostic models as time-varying variables was performed, calculating OS from the time of TACE to the time of the subsequent treatment. Total follow-up time for each patient was therefore split into several observation times accounting for each TACE procedure. Values of the likelihood ratio test (LRT) and Akaike information criterion (AIC) were used to compare different systems. Univariable and multivariable analyses were conducted to identify additional factors predictive of OS. We analyzed 1,610 TACE performed in 1,058 patients recorded in the Italian Liver Cancer database from 2008 through 2016. Results: The median OS of the enrolled patients was 41 months. According to LRT χ 2 and AIC values based on the time-varying analysis, mHAP-III achieved the best values (41.72 and 4,625.49, respectively, p < 0.0001), indicating the highest predictive performance compared with all other scores (HAP, mHAP-II, ALBI, and pALBI) and staging systems (MELD, ITALICA, CLIP, MESH, MESIAH, JIS, HKLC, and BCLC). In the multivariable Cox proportional hazards model, mHAP-III maintained an independent effect on OS (hazard ratio 1.31, 95% CI: 1.10–1.55, p < 0.0001). Time-varying age, alcoholic etiology, radiologic response to TACE, and performing ablation or surgery after TACE were additional significant variables resulting from the multivariable model. Conclusion: An innovative time-varying analysis revealed that mHAP-III was the most accurate model in predicting OS in patients with HCC undergoing TACE. Other clinical pre- and post-TACE variables were also found to be relevant for this prediction. |
| doi_str_mv | 10.1159/000513404 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1159_000513404</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A726988119</galeid><doaj_id>oai_doaj_org_article_857200417f064240bc64e5e1d201d577</doaj_id><sourcerecordid>A726988119</sourcerecordid><originalsourceid>FETCH-LOGICAL-c585t-b872a2faa8c712e3713ee427c1719247bd1f1620e7f72215da764c4e207dd253</originalsourceid><addsrcrecordid>eNptkkGLEzEUxwdR3LLuwbtIYC96mDXJJJOZi1CK2oGKBavXkGbeTFNnkm4yU9Hv4fc13a7VypJDIPm930v-vCR5TvANIbx8gzHmJGOYPUomJM9ZyjnPHicTSjOeElHyi-QqhG3EcIGxKMXT5CLLSiFwUU6SXyvTQ_pV-R_GtqifT5dpVVWoCmjYAProwoCmWo9eDYCWHmqjB-eRa9Dn0e_NXnXIWLRUgwE7BPTdDBs0h50anIauGzvl0Ux5bazrFfpia_CtOzRaeWWD8gN4ExWzDfQO-rXrzM-ocvZZ8qRRXYCr-_0yWb1_t5rN08WnD9Vsukg1L_iQrgtBFW2UKrQgFDJBMgBGhSaClJSJdU0aklMMohGUEl4rkTPNgGJR15Rnl0l11NZObeXOmz7mIJ0y8u7A-VbGNxrdgSy4oBgzIhqcM8rwWucMOJCaYlJzIaLr7dG1G9c91Drm4VV3Jj2_sWYjW7eXBRYiGqPg1b3Au9sRwiB7Ew4pKgtuDJJympOsEHe9rv9Dt270NiYVqTyLbxUF-0u1Kn7A2MbFvvoglVNB87IoCCkjdfMAFVcNvdHOQmPi-VnB62OB9i4ED83pjwTLw0TK00RG9uW_oZzIP_MXgRdH4JvyLfgTcKq_fvB6Uc2OhNzVTfYbr0TuoA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2563857784</pqid></control><display><type>article</type><title>Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization</title><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Karger Open Access</source><creator>Campani, Claudia ; Vitale, Alessandro ; Dragoni, Gabriele ; Arena, Umberto ; Laffi, Giacomo ; Cillo, Umberto ; Giannini, Edoardo G. ; Tovoli, Francesco ; Rapaccini, Gian Ludovico ; Di Marco, Maria ; Caturelli, Eugenio ; Zoli, Marco ; Sacco, Rodolfo ; Cabibbo, Giuseppe ; Mega, Andrea ; Guarino, Maria ; Gasbarrini, Antonio ; Svegliati-Baroni, Gianluca ; Foschi, Francesco Giuseppe ; Biasini, Elisabetta ; Masotto, Alberto ; Nardone, Gerardo ; Raimondo, Giovanni ; Azzaroli, Francesco ; Vidili, Gianpaolo ; Brunetto, Maurizia Rossana ; Farinati, Fabio ; Trevisani, Franco ; Marra, Fabio</creator><creatorcontrib>Campani, Claudia ; Vitale, Alessandro ; Dragoni, Gabriele ; Arena, Umberto ; Laffi, Giacomo ; Cillo, Umberto ; Giannini, Edoardo G. ; Tovoli, Francesco ; Rapaccini, Gian Ludovico ; Di Marco, Maria ; Caturelli, Eugenio ; Zoli, Marco ; Sacco, Rodolfo ; Cabibbo, Giuseppe ; Mega, Andrea ; Guarino, Maria ; Gasbarrini, Antonio ; Svegliati-Baroni, Gianluca ; Foschi, Francesco Giuseppe ; Biasini, Elisabetta ; Masotto, Alberto ; Nardone, Gerardo ; Raimondo, Giovanni ; Azzaroli, Francesco ; Vidili, Gianpaolo ; Brunetto, Maurizia Rossana ; Farinati, Fabio ; Trevisani, Franco ; Marra, Fabio ; ITA.LI.CA Group</creatorcontrib><description>Introduction: The prognosis of patients undergoing transarterial chemoembolization (TACE) is extremely variable, and a confounding factor is that TACE is often repeated several times. We retrospectively evaluated the accuracy of different prognostic scores and staging systems in estimating overall survival (OS) in patients with hepatocellular carcinoma (HCC). Methods: An analysis considering prognostic models as time-varying variables was performed, calculating OS from the time of TACE to the time of the subsequent treatment. Total follow-up time for each patient was therefore split into several observation times accounting for each TACE procedure. Values of the likelihood ratio test (LRT) and Akaike information criterion (AIC) were used to compare different systems. Univariable and multivariable analyses were conducted to identify additional factors predictive of OS. We analyzed 1,610 TACE performed in 1,058 patients recorded in the Italian Liver Cancer database from 2008 through 2016. Results: The median OS of the enrolled patients was 41 months. According to LRT χ 2 and AIC values based on the time-varying analysis, mHAP-III achieved the best values (41.72 and 4,625.49, respectively, p < 0.0001), indicating the highest predictive performance compared with all other scores (HAP, mHAP-II, ALBI, and pALBI) and staging systems (MELD, ITALICA, CLIP, MESH, MESIAH, JIS, HKLC, and BCLC). In the multivariable Cox proportional hazards model, mHAP-III maintained an independent effect on OS (hazard ratio 1.31, 95% CI: 1.10–1.55, p < 0.0001). Time-varying age, alcoholic etiology, radiologic response to TACE, and performing ablation or surgery after TACE were additional significant variables resulting from the multivariable model. Conclusion: An innovative time-varying analysis revealed that mHAP-III was the most accurate model in predicting OS in patients with HCC undergoing TACE. Other clinical pre- and post-TACE variables were also found to be relevant for this prediction.</description><identifier>ISSN: 2235-1795</identifier><identifier>EISSN: 1664-5553</identifier><identifier>DOI: 10.1159/000513404</identifier><identifier>PMID: 33977089</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Ablation ; Ablation (Surgery) ; Accuracy ; albi grade ; barcelona clinic liver cancer ; Cancer ; cancer of the liver italian program ; Cancer therapies ; Care and treatment ; Chemoembolization ; Clinical medicine ; Development and progression ; Embolization ; Hepatitis ; Hepatoma ; italica staging system ; Liver ; Liver cancer ; Liver diseases ; Medical prognosis ; Medical research ; Medicine, Experimental ; mesiah ; Original Paper ; Patient outcomes ; Patients ; Prognosis ; Surgical mesh ; Survival analysis ; Transplants & implants ; Variables</subject><ispartof>Liver cancer (Basel ), 2021-04, Vol.10 (2), p.126-136</ispartof><rights>2021 The Author(s). Published by S. Karger AG, Basel</rights><rights>Copyright © 2021 by S. Karger AG, Basel.</rights><rights>COPYRIGHT 2021 S. Karger AG</rights><rights>2021 The Author(s). Published by S. Karger AG, Basel . This work is licensed under the Creative Commons Attribution – Non-Commercial – No Derivatives License http://creativecommons.org/licenses/by-nc-nd/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2021 by S. Karger AG, Basel 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c585t-b872a2faa8c712e3713ee427c1719247bd1f1620e7f72215da764c4e207dd253</citedby><cites>FETCH-LOGICAL-c585t-b872a2faa8c712e3713ee427c1719247bd1f1620e7f72215da764c4e207dd253</cites><orcidid>0000-0002-8350-1155 ; 0000-0001-5752-5113 ; 0000-0003-4863-6924 ; 0000-0002-0946-3859 ; 0000-0001-8629-0878</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077424/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077424/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,27612,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33977089$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Campani, Claudia</creatorcontrib><creatorcontrib>Vitale, Alessandro</creatorcontrib><creatorcontrib>Dragoni, Gabriele</creatorcontrib><creatorcontrib>Arena, Umberto</creatorcontrib><creatorcontrib>Laffi, Giacomo</creatorcontrib><creatorcontrib>Cillo, Umberto</creatorcontrib><creatorcontrib>Giannini, Edoardo G.</creatorcontrib><creatorcontrib>Tovoli, Francesco</creatorcontrib><creatorcontrib>Rapaccini, Gian Ludovico</creatorcontrib><creatorcontrib>Di Marco, Maria</creatorcontrib><creatorcontrib>Caturelli, Eugenio</creatorcontrib><creatorcontrib>Zoli, Marco</creatorcontrib><creatorcontrib>Sacco, Rodolfo</creatorcontrib><creatorcontrib>Cabibbo, Giuseppe</creatorcontrib><creatorcontrib>Mega, Andrea</creatorcontrib><creatorcontrib>Guarino, Maria</creatorcontrib><creatorcontrib>Gasbarrini, Antonio</creatorcontrib><creatorcontrib>Svegliati-Baroni, Gianluca</creatorcontrib><creatorcontrib>Foschi, Francesco Giuseppe</creatorcontrib><creatorcontrib>Biasini, Elisabetta</creatorcontrib><creatorcontrib>Masotto, Alberto</creatorcontrib><creatorcontrib>Nardone, Gerardo</creatorcontrib><creatorcontrib>Raimondo, Giovanni</creatorcontrib><creatorcontrib>Azzaroli, Francesco</creatorcontrib><creatorcontrib>Vidili, Gianpaolo</creatorcontrib><creatorcontrib>Brunetto, Maurizia Rossana</creatorcontrib><creatorcontrib>Farinati, Fabio</creatorcontrib><creatorcontrib>Trevisani, Franco</creatorcontrib><creatorcontrib>Marra, Fabio</creatorcontrib><creatorcontrib>ITA.LI.CA Group</creatorcontrib><title>Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization</title><title>Liver cancer (Basel )</title><addtitle>Liver Cancer</addtitle><description>Introduction: The prognosis of patients undergoing transarterial chemoembolization (TACE) is extremely variable, and a confounding factor is that TACE is often repeated several times. We retrospectively evaluated the accuracy of different prognostic scores and staging systems in estimating overall survival (OS) in patients with hepatocellular carcinoma (HCC). Methods: An analysis considering prognostic models as time-varying variables was performed, calculating OS from the time of TACE to the time of the subsequent treatment. Total follow-up time for each patient was therefore split into several observation times accounting for each TACE procedure. Values of the likelihood ratio test (LRT) and Akaike information criterion (AIC) were used to compare different systems. Univariable and multivariable analyses were conducted to identify additional factors predictive of OS. We analyzed 1,610 TACE performed in 1,058 patients recorded in the Italian Liver Cancer database from 2008 through 2016. Results: The median OS of the enrolled patients was 41 months. According to LRT χ 2 and AIC values based on the time-varying analysis, mHAP-III achieved the best values (41.72 and 4,625.49, respectively, p < 0.0001), indicating the highest predictive performance compared with all other scores (HAP, mHAP-II, ALBI, and pALBI) and staging systems (MELD, ITALICA, CLIP, MESH, MESIAH, JIS, HKLC, and BCLC). In the multivariable Cox proportional hazards model, mHAP-III maintained an independent effect on OS (hazard ratio 1.31, 95% CI: 1.10–1.55, p < 0.0001). Time-varying age, alcoholic etiology, radiologic response to TACE, and performing ablation or surgery after TACE were additional significant variables resulting from the multivariable model. Conclusion: An innovative time-varying analysis revealed that mHAP-III was the most accurate model in predicting OS in patients with HCC undergoing TACE. Other clinical pre- and post-TACE variables were also found to be relevant for this prediction.</description><subject>Ablation</subject><subject>Ablation (Surgery)</subject><subject>Accuracy</subject><subject>albi grade</subject><subject>barcelona clinic liver cancer</subject><subject>Cancer</subject><subject>cancer of the liver italian program</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Chemoembolization</subject><subject>Clinical medicine</subject><subject>Development and progression</subject><subject>Embolization</subject><subject>Hepatitis</subject><subject>Hepatoma</subject><subject>italica staging system</subject><subject>Liver</subject><subject>Liver cancer</subject><subject>Liver diseases</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>mesiah</subject><subject>Original Paper</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Surgical mesh</subject><subject>Survival analysis</subject><subject>Transplants & implants</subject><subject>Variables</subject><issn>2235-1795</issn><issn>1664-5553</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>M--</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNptkkGLEzEUxwdR3LLuwbtIYC96mDXJJJOZi1CK2oGKBavXkGbeTFNnkm4yU9Hv4fc13a7VypJDIPm930v-vCR5TvANIbx8gzHmJGOYPUomJM9ZyjnPHicTSjOeElHyi-QqhG3EcIGxKMXT5CLLSiFwUU6SXyvTQ_pV-R_GtqifT5dpVVWoCmjYAProwoCmWo9eDYCWHmqjB-eRa9Dn0e_NXnXIWLRUgwE7BPTdDBs0h50anIauGzvl0Ux5bazrFfpia_CtOzRaeWWD8gN4ExWzDfQO-rXrzM-ocvZZ8qRRXYCr-_0yWb1_t5rN08WnD9Vsukg1L_iQrgtBFW2UKrQgFDJBMgBGhSaClJSJdU0aklMMohGUEl4rkTPNgGJR15Rnl0l11NZObeXOmz7mIJ0y8u7A-VbGNxrdgSy4oBgzIhqcM8rwWucMOJCaYlJzIaLr7dG1G9c91Drm4VV3Jj2_sWYjW7eXBRYiGqPg1b3Au9sRwiB7Ew4pKgtuDJJympOsEHe9rv9Dt270NiYVqTyLbxUF-0u1Kn7A2MbFvvoglVNB87IoCCkjdfMAFVcNvdHOQmPi-VnB62OB9i4ED83pjwTLw0TK00RG9uW_oZzIP_MXgRdH4JvyLfgTcKq_fvB6Uc2OhNzVTfYbr0TuoA</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Campani, Claudia</creator><creator>Vitale, Alessandro</creator><creator>Dragoni, Gabriele</creator><creator>Arena, Umberto</creator><creator>Laffi, Giacomo</creator><creator>Cillo, Umberto</creator><creator>Giannini, Edoardo G.</creator><creator>Tovoli, Francesco</creator><creator>Rapaccini, Gian Ludovico</creator><creator>Di Marco, Maria</creator><creator>Caturelli, Eugenio</creator><creator>Zoli, Marco</creator><creator>Sacco, Rodolfo</creator><creator>Cabibbo, Giuseppe</creator><creator>Mega, Andrea</creator><creator>Guarino, Maria</creator><creator>Gasbarrini, Antonio</creator><creator>Svegliati-Baroni, Gianluca</creator><creator>Foschi, Francesco Giuseppe</creator><creator>Biasini, Elisabetta</creator><creator>Masotto, Alberto</creator><creator>Nardone, Gerardo</creator><creator>Raimondo, Giovanni</creator><creator>Azzaroli, Francesco</creator><creator>Vidili, Gianpaolo</creator><creator>Brunetto, Maurizia Rossana</creator><creator>Farinati, Fabio</creator><creator>Trevisani, Franco</creator><creator>Marra, Fabio</creator><general>S. Karger AG</general><general>Karger Publishers</general><scope>M--</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-8350-1155</orcidid><orcidid>https://orcid.org/0000-0001-5752-5113</orcidid><orcidid>https://orcid.org/0000-0003-4863-6924</orcidid><orcidid>https://orcid.org/0000-0002-0946-3859</orcidid><orcidid>https://orcid.org/0000-0001-8629-0878</orcidid></search><sort><creationdate>20210401</creationdate><title>Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization</title><author>Campani, Claudia ; Vitale, Alessandro ; Dragoni, Gabriele ; Arena, Umberto ; Laffi, Giacomo ; Cillo, Umberto ; Giannini, Edoardo G. ; Tovoli, Francesco ; Rapaccini, Gian Ludovico ; Di Marco, Maria ; Caturelli, Eugenio ; Zoli, Marco ; Sacco, Rodolfo ; Cabibbo, Giuseppe ; Mega, Andrea ; Guarino, Maria ; Gasbarrini, Antonio ; Svegliati-Baroni, Gianluca ; Foschi, Francesco Giuseppe ; Biasini, Elisabetta ; Masotto, Alberto ; Nardone, Gerardo ; Raimondo, Giovanni ; Azzaroli, Francesco ; Vidili, Gianpaolo ; Brunetto, Maurizia Rossana ; Farinati, Fabio ; Trevisani, Franco ; Marra, Fabio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c585t-b872a2faa8c712e3713ee427c1719247bd1f1620e7f72215da764c4e207dd253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Ablation</topic><topic>Ablation (Surgery)</topic><topic>Accuracy</topic><topic>albi grade</topic><topic>barcelona clinic liver cancer</topic><topic>Cancer</topic><topic>cancer of the liver italian program</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Chemoembolization</topic><topic>Clinical medicine</topic><topic>Development and progression</topic><topic>Embolization</topic><topic>Hepatitis</topic><topic>Hepatoma</topic><topic>italica staging system</topic><topic>Liver</topic><topic>Liver cancer</topic><topic>Liver diseases</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>mesiah</topic><topic>Original Paper</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Surgical mesh</topic><topic>Survival analysis</topic><topic>Transplants & implants</topic><topic>Variables</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Campani, Claudia</creatorcontrib><creatorcontrib>Vitale, Alessandro</creatorcontrib><creatorcontrib>Dragoni, Gabriele</creatorcontrib><creatorcontrib>Arena, Umberto</creatorcontrib><creatorcontrib>Laffi, Giacomo</creatorcontrib><creatorcontrib>Cillo, Umberto</creatorcontrib><creatorcontrib>Giannini, Edoardo G.</creatorcontrib><creatorcontrib>Tovoli, Francesco</creatorcontrib><creatorcontrib>Rapaccini, Gian Ludovico</creatorcontrib><creatorcontrib>Di Marco, Maria</creatorcontrib><creatorcontrib>Caturelli, Eugenio</creatorcontrib><creatorcontrib>Zoli, Marco</creatorcontrib><creatorcontrib>Sacco, Rodolfo</creatorcontrib><creatorcontrib>Cabibbo, Giuseppe</creatorcontrib><creatorcontrib>Mega, Andrea</creatorcontrib><creatorcontrib>Guarino, Maria</creatorcontrib><creatorcontrib>Gasbarrini, Antonio</creatorcontrib><creatorcontrib>Svegliati-Baroni, Gianluca</creatorcontrib><creatorcontrib>Foschi, Francesco Giuseppe</creatorcontrib><creatorcontrib>Biasini, Elisabetta</creatorcontrib><creatorcontrib>Masotto, Alberto</creatorcontrib><creatorcontrib>Nardone, Gerardo</creatorcontrib><creatorcontrib>Raimondo, Giovanni</creatorcontrib><creatorcontrib>Azzaroli, Francesco</creatorcontrib><creatorcontrib>Vidili, Gianpaolo</creatorcontrib><creatorcontrib>Brunetto, Maurizia Rossana</creatorcontrib><creatorcontrib>Farinati, Fabio</creatorcontrib><creatorcontrib>Trevisani, Franco</creatorcontrib><creatorcontrib>Marra, Fabio</creatorcontrib><creatorcontrib>ITA.LI.CA Group</creatorcontrib><collection>Karger Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Liver cancer (Basel )</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Campani, Claudia</au><au>Vitale, Alessandro</au><au>Dragoni, Gabriele</au><au>Arena, Umberto</au><au>Laffi, Giacomo</au><au>Cillo, Umberto</au><au>Giannini, Edoardo G.</au><au>Tovoli, Francesco</au><au>Rapaccini, Gian Ludovico</au><au>Di Marco, Maria</au><au>Caturelli, Eugenio</au><au>Zoli, Marco</au><au>Sacco, Rodolfo</au><au>Cabibbo, Giuseppe</au><au>Mega, Andrea</au><au>Guarino, Maria</au><au>Gasbarrini, Antonio</au><au>Svegliati-Baroni, Gianluca</au><au>Foschi, Francesco Giuseppe</au><au>Biasini, Elisabetta</au><au>Masotto, Alberto</au><au>Nardone, Gerardo</au><au>Raimondo, Giovanni</au><au>Azzaroli, Francesco</au><au>Vidili, Gianpaolo</au><au>Brunetto, Maurizia Rossana</au><au>Farinati, Fabio</au><au>Trevisani, Franco</au><au>Marra, Fabio</au><aucorp>ITA.LI.CA Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization</atitle><jtitle>Liver cancer (Basel )</jtitle><addtitle>Liver Cancer</addtitle><date>2021-04-01</date><risdate>2021</risdate><volume>10</volume><issue>2</issue><spage>126</spage><epage>136</epage><pages>126-136</pages><issn>2235-1795</issn><eissn>1664-5553</eissn><abstract>Introduction: The prognosis of patients undergoing transarterial chemoembolization (TACE) is extremely variable, and a confounding factor is that TACE is often repeated several times. We retrospectively evaluated the accuracy of different prognostic scores and staging systems in estimating overall survival (OS) in patients with hepatocellular carcinoma (HCC). Methods: An analysis considering prognostic models as time-varying variables was performed, calculating OS from the time of TACE to the time of the subsequent treatment. Total follow-up time for each patient was therefore split into several observation times accounting for each TACE procedure. Values of the likelihood ratio test (LRT) and Akaike information criterion (AIC) were used to compare different systems. Univariable and multivariable analyses were conducted to identify additional factors predictive of OS. We analyzed 1,610 TACE performed in 1,058 patients recorded in the Italian Liver Cancer database from 2008 through 2016. Results: The median OS of the enrolled patients was 41 months. According to LRT χ 2 and AIC values based on the time-varying analysis, mHAP-III achieved the best values (41.72 and 4,625.49, respectively, p < 0.0001), indicating the highest predictive performance compared with all other scores (HAP, mHAP-II, ALBI, and pALBI) and staging systems (MELD, ITALICA, CLIP, MESH, MESIAH, JIS, HKLC, and BCLC). In the multivariable Cox proportional hazards model, mHAP-III maintained an independent effect on OS (hazard ratio 1.31, 95% CI: 1.10–1.55, p < 0.0001). Time-varying age, alcoholic etiology, radiologic response to TACE, and performing ablation or surgery after TACE were additional significant variables resulting from the multivariable model. Conclusion: An innovative time-varying analysis revealed that mHAP-III was the most accurate model in predicting OS in patients with HCC undergoing TACE. Other clinical pre- and post-TACE variables were also found to be relevant for this prediction.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>33977089</pmid><doi>10.1159/000513404</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-8350-1155</orcidid><orcidid>https://orcid.org/0000-0001-5752-5113</orcidid><orcidid>https://orcid.org/0000-0003-4863-6924</orcidid><orcidid>https://orcid.org/0000-0002-0946-3859</orcidid><orcidid>https://orcid.org/0000-0001-8629-0878</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2235-1795 |
| ispartof | Liver cancer (Basel ), 2021-04, Vol.10 (2), p.126-136 |
| issn | 2235-1795 1664-5553 |
| language | eng |
| recordid | cdi_crossref_primary_10_1159_000513404 |
| source | DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Karger Open Access |
| subjects | Ablation Ablation (Surgery) Accuracy albi grade barcelona clinic liver cancer Cancer cancer of the liver italian program Cancer therapies Care and treatment Chemoembolization Clinical medicine Development and progression Embolization Hepatitis Hepatoma italica staging system Liver Liver cancer Liver diseases Medical prognosis Medical research Medicine, Experimental mesiah Original Paper Patient outcomes Patients Prognosis Surgical mesh Survival analysis Transplants & implants Variables |
| title | Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T14%3A02%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Time-Varying%20mHAP-III%20Is%20the%20Most%20Accurate%20Predictor%20of%20Survival%20in%20Patients%20with%20Hepatocellular%20Carcinoma%20Undergoing%20Transarterial%20Chemoembolization&rft.jtitle=Liver%20cancer%20(Basel%20)&rft.au=Campani,%20Claudia&rft.aucorp=ITA.LI.CA%20Group&rft.date=2021-04-01&rft.volume=10&rft.issue=2&rft.spage=126&rft.epage=136&rft.pages=126-136&rft.issn=2235-1795&rft.eissn=1664-5553&rft_id=info:doi/10.1159/000513404&rft_dat=%3Cgale_cross%3EA726988119%3C/gale_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2563857784&rft_id=info:pmid/33977089&rft_galeid=A726988119&rft_doaj_id=oai_doaj_org_article_857200417f064240bc64e5e1d201d577&rfr_iscdi=true |